KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Debt (2021 - 2025)

Pacira BioSciences (PCRX) has 9 years of Non-Current Debt data on record, last reported at $372.2 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 2.96% year-over-year to $372.2 million; the TTM value through Dec 2025 reached $372.2 million, down 2.96%, while the annual FY2025 figure was $372.2 million, 2.96% down from the prior year.
  • Non-Current Debt reached $372.2 million in Q4 2025 per PCRX's latest filing, down from $376.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $383.5 million in Q4 2024 and bottomed at $97.8 million in Q2 2025.
  • Average Non-Current Debt over 5 years is $218.1 million, with a median of $137.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: crashed 61.93% in 2023, then surged 252.0% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $335.3 million in 2021, then decreased by 25.12% to $251.1 million in 2022, then crashed by 54.11% to $115.2 million in 2023, then surged by 232.93% to $383.5 million in 2024, then decreased by 2.96% to $372.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $372.2 million in Q4 2025, $376.7 million in Q3 2025, and $97.8 million in Q2 2025.